GB201814362D0 - Composition and process for preparing vaccine - Google Patents

Composition and process for preparing vaccine

Info

Publication number
GB201814362D0
GB201814362D0 GBGB1814362.8A GB201814362A GB201814362D0 GB 201814362 D0 GB201814362 D0 GB 201814362D0 GB 201814362 A GB201814362 A GB 201814362A GB 201814362 D0 GB201814362 D0 GB 201814362D0
Authority
GB
United Kingdom
Prior art keywords
composition
preparing vaccine
vaccine
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1814362.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Treos Bio Zrt
Original Assignee
Treos Bio Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treos Bio Zrt filed Critical Treos Bio Zrt
Priority to GBGB1814362.8A priority Critical patent/GB201814362D0/en
Publication of GB201814362D0 publication Critical patent/GB201814362D0/en
Priority to CN201980071000.1A priority patent/CN113383009A/zh
Priority to KR1020217009975A priority patent/KR20210086610A/ko
Priority to EA202190669A priority patent/EA202190669A1/ru
Priority to MX2021002543A priority patent/MX2021002543A/es
Priority to JP2021512906A priority patent/JP2021535749A/ja
Priority to CA3110923A priority patent/CA3110923A1/en
Priority to MA053544A priority patent/MA53544A/fr
Priority to AU2019334261A priority patent/AU2019334261B2/en
Priority to PCT/EP2019/073481 priority patent/WO2020048995A1/en
Priority to BR112021004075-7A priority patent/BR112021004075A2/pt
Priority to SG11202101881UA priority patent/SG11202101881UA/en
Priority to US16/559,430 priority patent/US20200069786A1/en
Priority to EP19765219.1A priority patent/EP3847185A1/en
Priority to US17/249,362 priority patent/US20210236611A1/en
Priority to IL281220A priority patent/IL281220A/en
Priority to CL2021000534A priority patent/CL2021000534A1/es
Priority to CONC2021/0004028A priority patent/CO2021004028A2/es
Priority to US17/650,360 priority patent/US20220160854A1/en
Priority to JP2025019485A priority patent/JP2025069437A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1814362.8A 2018-09-04 2018-09-04 Composition and process for preparing vaccine Ceased GB201814362D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB1814362.8A GB201814362D0 (en) 2018-09-04 2018-09-04 Composition and process for preparing vaccine
EP19765219.1A EP3847185A1 (en) 2018-09-04 2019-09-03 Process for preparing vaccine compositions
AU2019334261A AU2019334261B2 (en) 2018-09-04 2019-09-03 Process for preparing vaccine compositions
BR112021004075-7A BR112021004075A2 (pt) 2018-09-04 2019-09-03 composição e processo para preparar vacina
EA202190669A EA202190669A1 (ru) 2018-09-04 2019-09-03 Процесс получения вакцинной композиции
MX2021002543A MX2021002543A (es) 2018-09-04 2019-09-03 Proceso para la preparacion de composiciones de vacunas.
JP2021512906A JP2021535749A (ja) 2018-09-04 2019-09-03 ワクチン組成物を調製するためのプロセス
CA3110923A CA3110923A1 (en) 2018-09-04 2019-09-03 Process for preparing vaccine compositions
MA053544A MA53544A (fr) 2018-09-04 2019-09-03 Procédé de préparation de compositions de vaccin
CN201980071000.1A CN113383009A (zh) 2018-09-04 2019-09-03 制备疫苗组合物的方法
PCT/EP2019/073481 WO2020048995A1 (en) 2018-09-04 2019-09-03 Process for preparing vaccine compositions
KR1020217009975A KR20210086610A (ko) 2018-09-04 2019-09-03 백신 조성물의 제조 방법
SG11202101881UA SG11202101881UA (en) 2018-09-04 2019-09-03 Process for preparing vaccine compositions
US16/559,430 US20200069786A1 (en) 2018-09-04 2019-09-03 Composition and process for preparing vaccine
US17/249,362 US20210236611A1 (en) 2018-09-04 2021-02-26 Composition and process for preparing vaccine
IL281220A IL281220A (en) 2018-09-04 2021-03-03 Process for preparing vaccine compositions
CL2021000534A CL2021000534A1 (es) 2018-09-04 2021-03-04 Proceso para la preparación de composiciones de vacunas
CONC2021/0004028A CO2021004028A2 (es) 2018-09-04 2021-03-30 Proceso para la preparación de composiciones de vacunas
US17/650,360 US20220160854A1 (en) 2018-09-04 2022-02-08 Composition and process for preparing vaccine
JP2025019485A JP2025069437A (ja) 2018-09-04 2025-02-07 ワクチン組成物を調製するためのプロセス

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1814362.8A GB201814362D0 (en) 2018-09-04 2018-09-04 Composition and process for preparing vaccine

Publications (1)

Publication Number Publication Date
GB201814362D0 true GB201814362D0 (en) 2018-10-17

Family

ID=63920945

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1814362.8A Ceased GB201814362D0 (en) 2018-09-04 2018-09-04 Composition and process for preparing vaccine

Country Status (17)

Country Link
US (3) US20200069786A1 (https=)
EP (1) EP3847185A1 (https=)
JP (2) JP2021535749A (https=)
KR (1) KR20210086610A (https=)
CN (1) CN113383009A (https=)
AU (1) AU2019334261B2 (https=)
BR (1) BR112021004075A2 (https=)
CA (1) CA3110923A1 (https=)
CL (1) CL2021000534A1 (https=)
CO (1) CO2021004028A2 (https=)
EA (1) EA202190669A1 (https=)
GB (1) GB201814362D0 (https=)
IL (1) IL281220A (https=)
MA (1) MA53544A (https=)
MX (1) MX2021002543A (https=)
SG (1) SG11202101881UA (https=)
WO (1) WO2020048995A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110651189B (zh) 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
TWI869426B (zh) * 2019-07-30 2025-01-11 大學健康網絡 Ｔ細胞受體及其使用方法
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
CA3176326A1 (en) * 2020-04-20 2021-10-28 Boris SIMOVSKI Method and system for identifying one or more candidate regions of one or more source proteins that are predicted to instigate an immunogenic response, and method for creating a vaccine
US20230190902A1 (en) * 2020-05-29 2023-06-22 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
CN111617238B (zh) * 2020-06-02 2022-12-13 苏州药明康德新药开发有限公司 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法
EP3945320A1 (en) * 2020-07-29 2022-02-02 Corporació Sanitària Parc Taulí Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein
EP4236981A1 (en) * 2020-10-28 2023-09-06 Follicum AB Peptides for use in skin and hair pigmentation
AU2022256469A1 (en) * 2021-04-14 2023-10-12 Academisch Ziekenhuis Leiden Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
CN114195861A (zh) * 2022-01-05 2022-03-18 许昌学院 亲和肽
CN115785211B (zh) * 2022-06-10 2024-09-24 河北博海生物工程开发有限公司 肺癌特异性分子靶标04及其用途
CN115785204B (zh) * 2022-06-10 2024-02-13 河北博海生物工程开发有限公司 肺癌特异性分子靶标08及其用途
WO2025227519A1 (zh) * 2024-04-29 2025-11-06 北京臻知医学科技有限责任公司 一种肿瘤疫苗及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
GB0520067D0 (en) * 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
WO2008035350A1 (en) * 2006-09-21 2008-03-27 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2012051282A2 (en) * 2010-10-14 2012-04-19 The Ohio State University Research Foundation Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
CN110651189B (zh) 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides

Also Published As

Publication number Publication date
EA202190669A1 (ru) 2021-06-03
MX2021002543A (es) 2021-08-11
IL281220A (en) 2021-04-29
CL2021000534A1 (es) 2021-09-24
US20200069786A1 (en) 2020-03-05
BR112021004075A2 (pt) 2021-05-25
SG11202101881UA (en) 2021-03-30
CN113383009A (zh) 2021-09-10
CO2021004028A2 (es) 2021-06-21
AU2019334261B2 (en) 2025-04-10
US20220160854A1 (en) 2022-05-26
JP2025069437A (ja) 2025-04-30
EP3847185A1 (en) 2021-07-14
KR20210086610A (ko) 2021-07-08
JP2021535749A (ja) 2021-12-23
MA53544A (fr) 2021-07-14
WO2020048995A1 (en) 2020-03-12
US20210236611A1 (en) 2021-08-05
CA3110923A1 (en) 2020-03-12
AU2019334261A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
GB201814362D0 (en) Composition and process for preparing vaccine
SG11202010821TA (en) Vaccine composition
IL272281A (en) Methods and preparations for heterologous repRNA vaccines
IL274439A (en) Process for making Tapinaroff
GB202202474D0 (en) Bioengineered formulation, process for preparing and implementations thereof
IL256686A (en) Preparation method for lyophilized pharmaceutical preparations and pharmaceutical preparations prepared in this way
IL269459B (en) Adhesive preparation and method for its preparation
HUE052049T2 (hu) Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
GB201802339D0 (en) Immunogenic composition
IL268784B (en) Process for preparing bromotrichloromethane
GB201801566D0 (en) Methods and compositions for nanormulsion vaccine formulations
IL286587A (en) Preparations of d-methyrosine and methods for their preparation
IL278294A (en) HSV-2-DELTA-gD compositions and methods for their production and use
ZA202004349B (en) Fluoralkenyl compounds, process for preparation and use thereof
EP3231455A4 (en) Biocompatible composition and method for preparing same
ZA201908090B (en) Pharmaceutical composition and method for preparing same
IL273168A (en) A compound for an epidural vaccine of hepatitis B and its production
ZA201908452B (en) Improved process for preparing imetelstat
IL265403B (en) Process for preparing 3-fluoroalkyl-5-pyrazole carboxylates and 3-fluoroalkyl-5-pyrazole carboxylic acids
PL3615005T3 (pl) Kompozycje i sposoby dostarczania szczepionki
GB201703529D0 (en) Vaccine composition
GB2565419B (en) Process for preparing novel crystalline form of mesosulfuron-methyl and use thereof
HUE058725T2 (hu) Eljárás aminok elõállítására
GB201803692D0 (en) Immunogenic composition
PL3324971T3 (pl) Kompozycja zolpidemu i sposób jej wytwarzania

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)